Search Results

BioElectronics Corporation a developer of medical technology products, announces the results and publication of a study investigating the efficacy of its FDA-cleared pulsed-shortwave-therapy device in initiating a systemic anti-inflammatory response to improve functionality of canines diagnosed with osteoarthritis.

BioElectronics Corporation (https://www.bielcorp.com/ OTC: BIEL a developer of medical technology products, today announces the publication of a study investigating the treatment of phantom and residual limb pain using its pulsed shortwave therapy device.

BioElectronics Corporation releases an update from its Chairman, Richard Staelin, PhD.

The American Institute for Medical and Biological Engineering has announced the election of two researchers from The Feinstein Institutes for Medical Research to the AIMBE College of Fellows Class of 2024 for their contributions to the fields of medical and biological engineering, and particularly the field of bioelectronic medicine.

Salvia BioElectronics, a pioneering company focused on neuromodulation for severe migraine, announced the successful first implantation of their paper-thin neuromodulation solution.

Tivic Health® Systems, Inc. announced that the research study that the company is funding at The Feinstein Institutes for Medical Research has received study approval from the Institutional Review Board and has initiated study recruitment and enrollment for its novel non-invasive bioelectronic device approach to vagus nerve stimulation.

In a first-of-its-kind clinical trial, bioelectronic medicine researchers, engineers and surgeons at Northwell Health’s The Feinstein Institutes for Medical Research have successfully implanted microchips into the brain of a man living with paralysis, and have developed artificial intelligence algorithms to re-link his brain to his body and spinal cord.

Tivic Health ® Systems, Inc. announced today that enrollment in its pilot clinical study of a proprietary approach to non-invasive vagus nerve stimulation (VNS) has been completed.

BioElectronics Corporation announced via a Shareholder’s update that the Company has completed and undertaken additional clinical research and has received the initial stocking purchase order from its distribution partner, Stada.